Arham, A. B., Thomas, C., Castaneda, I., Ruder, S. F., Zakharia, Y., Appleman, L. J., Osborne, J. R., Philips, G., Nordquist, L., D'souza, A., Wulff-Burchfield, E. M., Posadas, E. M., Agarwal, N., Christos, P. J., Adra, N., Nanus, D. M., Tagawa, S. T. (2025). Updated follow up of a randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.172